Allarity Secures CLIA Certification for In-House DRP Testing — Allarity Therapeutics, Inc.

Event summary

Allarity Therapeutics obtained CLIA certification for its in-house laboratory in Horsholm, Denmark on July 7, 2026.
The certification allows Allarity to perform DRP® testing internally for U.S.-based clinical trials, including a pivotal trial of stenoparib in advanced ovarian cancer.
CLIA certification eliminates reliance on external labs, reducing turnaround times and long-term costs for stenoparib development.
Allarity's lab is now positioned as a preferred CLIA-certified partner for European companies pursuing U.S. clinical trials or commercialization.

The big picture

Allarity's CLIA certification is a strategic move to control its proprietary DRP® testing, a critical component for patient selection in precision oncology. This aligns with broader industry trends toward decentralized clinical trials and the growing demand for companion diagnostics that improve therapeutic outcomes. The certification also positions Allarity as a key player in bridging European biotech innovation with U.S. regulatory requirements.

What we're watching

Regulatory Strategy: Whether Allarity can sustain the operational efficiencies and cost savings from in-house CLIA-certified testing as it advances stenoparib toward FDA registration.
Commercial Opportunity: The pace at which Allarity Therapeutics Medical Laboratory attracts third-party biopharmaceutical clients seeking CLIA-compliant testing for U.S. trials.
Clinical Development: How the streamlined DRP® testing process impacts the enrollment and execution of the pivotal trial for stenoparib in platinum-resistant ovarian cancer.